Insider Trading History of Azria Rene Pierre

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Azria Rene Pierre since 2007. The trader's CIK number is 1201292. At the time of the last reporting, Azria Rene Pierre was the Director of Immune Pharmaceuticals Inc. (stock ticker symbol IMNPQ). Also see all insider trading activities at Immune Pharmaceuticals Inc.

Note that in the past AZRIA RENE PIERRE also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Immune Pharmaceuticals Inc (IMNP) by Azria Rene Pierre

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 IMNP 50,000 $73,850 0 $0 0 $0

Yearly summary of insider trading at Jarden Corp (JAH) by Azria Rene Pierre

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2012 JAH 0 $0 0 $0 29,000 $308,850
2011 JAH 0 $0 1,000 $35,400 0 $0
2008 JAH 3,000 $56,000 0 $0 0 $0
2007 JAH 1,700 $51,995 0 $0 0 $0


Insider trading activities at 2 companies by Azria Rene Pierre:

1. Immune Pharmaceuticals Inc (IMNP)

2. Jarden Corp (JAH)

Table 1. Insider trading of Immune Pharmaceuticals Inc (IMNP) by Azria Rene Pierre

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-09-14 IMNP Buy 50,000 1.48 73,850

Table 2. Insider trading of Jarden Corp (JAH) by Azria Rene Pierre

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2012-03-01 JAH Option Ex 29,000 10.65 308,850
2011-02-22 JAH Sale 1,000 35.40 35,400
2008-06-09 JAH Buy 2,000 18.00 36,000
2008-01-09 JAH Buy 1,000 20.00 20,000
2007-11-27 JAH Buy 700 26.00 18,200
2007-08-07 JAH Buy 1,000 33.80 33,795

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Azria Rene Pierre (Director of Immune Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.